On September 26th, 2024, ARCH Venture Partners announced it had closed ARCH Venture Fund XIII, a venture capital fund with over $3 billion to support the launch and growth of early-stage biotech companies. This latest fund builds on ARCH’s longstanding goal of investing in transformative healthcare solutions, with a focus on advanced therapies, AI, and other cutting-edge solutions. [Read more…]
RxCell Inc. Granted U.S. Patent for iPSC-based Cell Therapy
PARK CITY, Utah, September 19, 2024 – RxCell Inc. is pleased to announce the issuance of U.S. Patent 11,946,069 entitled “Method for Generating Multiple Cellular Products from Single Pluripotent Cell Source”, a significant advancement in the field of regenerative medicine. This patent, granted on April 2, 2024, provides RxCell with exclusive rights to induced pluripotent stem cell (iPSC)-derived cells for therapy across a broad spectrum of diseases. [Read more…]
GC Therapeutics Launches with $75M and Star-Studded Leadership to Scale Allogeneic iPSC-Derived Cell Therapies
-
TFome could revolutionize cell therapy by delivering off-the-shelf iPSC-based medicines at a pace up to 100X more rapidly than conventional methods via a single-step process with improved potency, efficiency, quality and cost
-
TFome™ is the world’s first “plug-and-play” iPSC cellular programming platform.
-
The company raised $75M from Cormorant Asset Management, Mubadala Capital, a16z Bio + Health, Medical Excellence Capital, Cercano Management, & Pear VC
Poseida Therapeutics Receives RMAT for P-BCMA-ALLO1 to Treat Relapsed/Refractory Multiple Myeloma
FDA evaluated RMAT application based on positive clinical data from ongoing Phase 1 study of P-BCMA-ALLO1; new clinical data from the study will be presented at the 21st International Myeloma Society Annual Meeting this month
RMAT designation recognizes potential of P-BCMA-ALLO1 to address significant unmet needs of multiple myeloma patients and enables increased dialogue with FDA throughout the development process
FUJIFILM Cellular Dynamics Introduces Human iPSC-derived Sensory Neurons to Advance Pain Research
MADISON, Wis., September 10, 2024 – FUJIFILM Cellular Dynamics, a leading global developer and manufacturer of human induced pluripotent stem cells (iPSCs) today announces the global commercial launch of its human iPSC-derived iCell® Sensory Neurons for scientists engaged in neuroscience research, drug discovery of novel pain medications, and analysis of neurotoxicity side effects. FUJIFILM Cellular Dynamics will present iCell Sensory Neurons and other key products in its market-leading neuroscience portfolio at the Society for Neuroscience annual conference in Chicago from October 5-9, 2024 and the Annual Pain Therapeutics Summit in Boston from October 28-29, 2024. [Read more…]
- « Previous Page
- 1
- …
- 84
- 85
- 86
- 87
- 88
- …
- 334
- Next Page »